XORTX Financial Statements From 2010 to 2026

XRTX Stock  USD 0.57  0.01  1.72%   
XORTX Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing XORTX Therapeutics' valuation are provided below:
Quarterly Earnings Growth
(0.97)
Market Capitalization
M
Earnings Share
(0.40)
We have found one hundred twenty available fundamental gauges for XORTX Therapeutics, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of XORTX Therapeutics prevalent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself for the next two years. Market Cap is likely to drop to about 2.4 M in 2026. Enterprise Value is likely to drop to about 956.3 K in 2026
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 1.1 M, Other Operating Expenses of 2.9 M or Total Operating Expenses of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.96. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with XORTX Stock
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

XORTX Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.4 M4.7 M3.5 M
Slightly volatile
Other Current Liabilities421.6 K730.5 K316.6 K
Slightly volatile
Total Current Liabilities884.7 K871.7 K625.9 K
Slightly volatile
Accounts Payable91.8 K96.6 K245.8 K
Slightly volatile
Cash3.9 M2.8 M2.5 M
Slightly volatile
Non Current Assets Total852.8 K1.6 M657.5 K
Slightly volatile
Cash And Short Term Investments3.9 M2.8 M2.5 M
Slightly volatile
Net Receivables32.9 K20.3 K21.6 K
Slightly volatile
Common Stock Shares Outstanding3.5 M3.3 MM
Slightly volatile
Liabilities And Stockholders Equity5.4 M4.7 M3.5 M
Slightly volatile
Total Liabilities828.1 K871.7 K1.2 M
Slightly volatile
Total Current Assets4.5 M3.1 M2.9 M
Slightly volatile
Short and Long Term Debt Total33.2 K34.9 K93.3 K
Slightly volatile
Other Current Assets202.6 K213.2 K325.7 K
Slightly volatile
Short Term Debt63.9 K34.9 K88.6 K
Slightly volatile
Intangible Assets184.6 K164.8 K236 K
Slightly volatile
Long Term Debt43.5 K49.7 K40.1 K
Slightly volatile
Deferred Long Term Liabilities133.8 K150.5 K164.3 K
Slightly volatile
Short and Long Term Debt43.4 K45.7 K137.6 K
Slightly volatile
Common Stock12.5 M21.3 M7.9 M
Slightly volatile
Property Plant Equipment151.6 K144.4 K54.9 K
Slightly volatile
Capital Stock14.3 M21.3 M10.2 M
Slightly volatile
Other Liabilities5.4 MM4.8 M
Slightly volatile
Current Deferred Revenue0.80.90.9824
Slightly volatile

XORTX Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative1.1 M1.8 M775.3 K
Slightly volatile
Other Operating Expenses2.9 M4.1 MM
Slightly volatile
Total Operating Expenses2.8 M4.1 MM
Slightly volatile
Depreciation And Amortization42.9 K64.1 K32.6 K
Slightly volatile
Research Development288.7 K303.9 K683.2 K
Slightly volatile
Reconciled Depreciation141.6 K134.9 K47.1 K
Slightly volatile
Cost Of Revenue171.8 K163.6 K52.6 K
Slightly volatile
Interest Income196.1 K293.5 K136.3 K
Slightly volatile
Selling And Marketing Expenses1.7 MM1.4 M
Slightly volatile

XORTX Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.1 MM2.1 M
Slightly volatile
Capital Expenditures32 K44.8 K30.2 K
Slightly volatile
End Period Cash Flow3.5 M2.8 M2.2 M
Slightly volatile
Stock Based Compensation239.1 K140.9 K209.4 K
Very volatile
Depreciation141.6 K134.9 K44.5 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables703.8 K670.3 K387.7 K
Slightly volatile
Capex To Depreciation0.00.00.7318
Slightly volatile
Payables Turnover1.811.720.4089
Slightly volatile
Average Inventory89.7 K90.6 K83.4 K
Very volatile
Cash Per Share1.861.111.6766
Slightly volatile
Days Payables Outstanding2092204.8 K
Slightly volatile
Tangible Asset Value157.8 K177.5 K193.8 K
Slightly volatile
Intangibles To Total Assets0.04890.05140.4621
Slightly volatile
Current Ratio4.493.184.1263
Slightly volatile
Capex Per Share0.00.00.1125
Slightly volatile
Average Receivables67.3 K64.1 K43 K
Slightly volatile
Interest Debt Per Share0.02120.02230.3935
Slightly volatile
Debt To Assets0.01030.01090.2147
Slightly volatile
Days Of Payables Outstanding2092204.8 K
Slightly volatile
Ebt Per Ebit1.310.931.1675
Pretty Stable
Quick Ratio4.483.184.1187
Slightly volatile
Net Income Per E B T0.590.660.7237
Slightly volatile
Cash Ratio3.912.943.5732
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.191.151.1357
Slightly volatile
Debt Ratio0.01030.01090.2147
Slightly volatile

XORTX Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.4 M4.4 MM
Slightly volatile
Enterprise Value956.3 K1.2 M1.1 M
Slightly volatile

XORTX Fundamental Market Drivers

Forward Price Earnings0.9621
Cash And Short Term Investments2.5 M

XORTX Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.80 
Cost Of Revenue163.6 K171.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.